MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis.

[1]  L. Staudt,et al.  Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. , 2017, Cancer cell.

[2]  M. Noguchi,et al.  MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma , 2017, British journal of haematology.

[3]  K. Hoang-Xuan,et al.  Clinical/Scientific Notes , 2011, Neurology.

[4]  R. Houot,et al.  Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial , 2016, Neuro-oncology.

[5]  M. Care,et al.  TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism. , 2016, Cancer research.

[6]  K. Dimopoulos,et al.  TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy , 2016, Acta neuropathologica communications.

[7]  T. Maehara,et al.  Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas , 2016, Neuropathology and applied neurobiology.

[8]  H. Aburatani,et al.  Genomic characterization of primary central nervous system lymphoma , 2016, Acta Neuropathologica.

[9]  Andrew J. Dunford,et al.  Targetable genetic features of primary testicular and primary central nervous system lymphomas. , 2014, Blood.

[10]  Akito Dobashi.  Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma. , 2016, Journal of clinical and experimental hematopathology : JCEH.

[11]  S. Mourah,et al.  Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. , 2015, Blood.

[12]  Roland Schmitz,et al.  Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma , 2015, Nature Medicine.

[13]  E. Thiel,et al.  Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma. , 2015, Neuro-oncology.

[14]  Y. Asmann,et al.  Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas , 2015, Clinical Cancer Research.

[15]  K. Yamazaki,et al.  Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations , 2015, Leukemia & lymphoma.

[16]  G. Bhagat,et al.  MYC Protein Expression in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System , 2014, PloS one.

[17]  K. Hoang-Xuan,et al.  Mutational analysis of primary central nervous system lymphoma , 2014, Oncotarget.

[18]  Y. Hasegawa,et al.  Prognosis Factors in Japanese Elderly Patients with Primary Central Nervous System Lymphoma Treated with a Nonradiation, Intermediate-Dose Methotrexate-Containing Regimen , 2014, Oncology Research and Treatment.

[19]  Stefano A Pileri,et al.  Diffuse large B-cell lymphoma. , 2013, Critical reviews in oncology/hematology.

[20]  Ju-Han Lee,et al.  MYD88 expression and L265P mutation in diffuse large B-cell lymphoma. , 2013, Human pathology.

[21]  David Dunson,et al.  Genetic heterogeneity of diffuse large B-cell lymphoma , 2013, Proceedings of the National Academy of Sciences.

[22]  Joseph M. Connors,et al.  Oncogenically active MYD88 mutations in human lymphoma , 2011, Nature.

[23]  Y. Hasegawa,et al.  A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma , 2010, International journal of hematology.